What is ERA Testing?
ERA (Endometrial Receptivity Array) testing is a molecular diagnostic tool that analyzes the expression of 238 genes in an endometrial biopsy to determine whether the endometrium is in its receptive phase and to identify the personalized window of implantation for each individual patient. 1
Biological Foundation
The ERA test is based on the transcriptomic signature that distinguishes the receptive endometrium from pre-receptive or post-receptive states. The test evaluates a specific set of 238 genes that are differentially expressed during the transition from pre-receptive to receptive endometrium, providing a molecular fingerprint of endometrial receptivity 1.
How ERA Works
- Endometrial biopsy is performed during what is presumed to be the window of implantation (typically cycle day 19-24 in natural cycles or after 5 days of progesterone in hormone replacement therapy cycles)
- The tissue sample undergoes gene expression analysis to assess the receptivity status
- Results classify the endometrium as:
- Receptive (R): Ready for embryo transfer
- Pre-receptive: Window of implantation has not yet opened
- Post-receptive: Window of implantation has closed
Clinical Applications
ERA is primarily used for patients with recurrent implantation failure (RIF), where it identifies displaced windows of implantation that may explain transfer failures 2. Studies show that 25.9-66.4% of RIF patients have a displaced window of implantation 3, 2, 4.
Pregnancy Outcomes with ERA-Guided Transfer
When personalized embryo transfer (pET) is performed based on ERA results:
- Clinical pregnancy rates: 51.7-88.6% in RIF patients 3, 2, 4
- Implantation rates: 33.9-63.7% 3, 2
- Live birth rates: 52.5-57.1% 4
These outcomes represent significant improvements compared to standard embryo transfer timing, particularly in the RIF population 3, 4.
Advantages Over Traditional Methods
ERA has proven superior to classical histological dating methods (Noyes criteria) for defining endometrial cycle phases 1. Traditional histological assessment lacks the accuracy and reproducibility needed for precise timing of embryo transfer 5.
Important Clinical Considerations
Patient Selection
ERA is most beneficial for:
- Patients with recurrent implantation failure (≥2-3 failed transfers with good quality embryos)
- Patients with repeated IVF failures despite optimal embryo quality
- Those with suspected endometrial factor infertility
Factors Associated with Displaced Window
- Increasing age: Older patients show higher rates of displaced WOI 4
- Number of previous failed transfers: More failures correlate with increased likelihood of displaced WOI 4
- History of induced abortion: May be a correlative factor 3
- Estrogen/Progesterone ratio: Optimal E2/P ratio (4.46-10.39 pg/ng) associated with lower displaced WOI rates 4
Limitations and Caveats
- Invasive procedure: Requires endometrial biopsy, necessitating cycle cancellation for testing
- Cost considerations: Additional expense beyond standard IVF treatment
- Validation requirement: Non-receptive results often require a second ERA test to confirm WOI displacement 2
- Not universally indicated: Benefit in general IVF population without RIF remains under investigation 1
Emerging Developments
Recent advances include development of non-invasive RNA-seq-based endometrial receptivity testing (nirsERT) using endometrial fluid analysis, which may eliminate the need for tissue biopsy while maintaining diagnostic accuracy 6, 7.